2 surseUrmărit de acum 10 h
<a href="https://www.fiercebiotech.com/biotech/its-cancer-and-inflammation-expansion-critical-mass-gileads-oday-eyes-companys-next-chapter" hreflang="en">CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’</a>
Cronologia relatărilor
Prima relatareacum 10 h<a href="https://www.fiercebiotech.com/biotech/its-cancer-and-inflammation-expansion-critical-mass-gileads-oday-eyes-companys-next-chapter" hreflang="en">CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’</a>
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.
Fierce Biotech•Darren Incorvaia
- Cea mai nouăacum 9 h
<a href="https://www.fiercepharma.com/biotech/its-cancer-and-inflammation-expansion-critical-mass-gileads-oday-eyes-companys-next-chapter" hreflang="en">CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’</a>
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.
Fierce Pharma•Darren Incorvaia